King’s College London and Wellcome have announced an agreement with the pharmaceutical company MSD. The collaboration and licence deal, made possible by the pioneering work of Professor Peter McNaughton from the Institute of Psychiatry, Psychology & Neuroscience at King’s, could lead to a new class of pain medications.

Under the agreement, negotiated by King’s IP & Licensing team and Wellcome’s Innovations team, King’s and Wellcome are eligible to receive up to £263 million in development and sales milestones, as well as royalties if a drug comes to market. MSD will be responsible for conducting lead optimisation, preclinical development and clinical trials.

Dr Daniel Gill, from Wellcome, said: ‘Professor McNaughton’s discovery that HCN2 plays an important role in how we feel pain opened a new avenue for treatments and we’re delighted that this Wellcome-funded work has reached the next stage of its development. We hope that bringing together world-leading pain researchers with the pharmaceutical company MSD, who have an excellent track record for bringing innovative new treatments to patients, will be a turning point in tackling chronic pain.’

For further information see King's College London's full news story.

Back to e-newsletter